Company intelligence / Profile preview

TriAgenics

Redmond, Oregon, United Statestriagenics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

TriAgenics has developed the Zero3 TBA system, a proprietary device-based treatment designed to prevent the formation of wisdom teeth by ablating developing third molar tooth buds. In multiple live animal trials, the procedure has shown no detectable tooth formation post-treatment and minimal adverse outcomes. The company is currently undergoing FDA premarket review and aims for U.S. market introduction soon[1][5].

Therapeutic areas: Other
Modalities: DeviceNon-pharmacological therapy (tooth bud ablation)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on TriAgenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriAgenics.

Explore the full profile